Biomarkers in Cardiology: A Critical Appraisal of Historical Successes, Pitfalls, and Emerging Uses

In preventive cardiology, low-density lipoprotein cholesterol and blood pressure are validated surrogate endpoints, with multiple randomized trials demonstrating that their reduction improves cardiovascular morbidity and mortality. In contrast, raising high-density lipoprotein cholesterol (HDL-C) with niacin or cholesteryl ester transfer protein inhibitors failed to improve outcomes despite promising observational data and biological plausibility. In the Cardiac Arrhythmia Suppression Trial of class IC antiarrhythmics to suppress premature ventricular complexes, biomarker-targeted therapy increased mortality. Contemporary biomarkers, including lipoprotein(a), coronary artery calcium scoring, and high-sensitivity C-reactive protein, are increasingly used to refine risk and guide therapy. However, despite favorable guideline recommendations, randomized trials showing that biomarker-guided or biomarker-targeted treatment improves hard clinical endpoints are lacking. This review presents historical biomarker reversals in cardiology and critically appraises the evidence supporting emerging biomarkers. Our core argument is that practice recommendations for biomarker-guided therapy should await appropriately designed randomized trials adequately powered for cardiovascular events and mortality.

Authors

Institutions

Publication Details

Journal
Cardiology in Review
Published
2026-11-17
DOI
https://doi.org/10.1097/crd.0000000000001546
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Biomarkers in Cardiology: A Critical Appraisal of Historical Successes, Pitfalls, and Emerging Uses

Areez Shafqat, Isra Khan, Douglas S. Paauw, Abdullah Shaik et al.
Cardiology in Review
Lipoproteins and Cardiovascular Health
article

Biomarkers in Cardiology: A Critical Appraisal of Historical Successes, Pitfalls, and Emerging Uses

Areez Shafqat, Isra Khan, Douglas S. Paauw, Abdullah Shaik, Mohammad Kazi, Ahmed ElShaer
article en

Abstract

In preventive cardiology, low-density lipoprotein cholesterol and blood pressure are validated surrogate endpoints, with multiple randomized trials demonstrating that their reduction improves cardiovascular morbidity and mortality. In contrast, raising high-density lipoprotein cholesterol (HDL-C) with niacin or cholesteryl ester transfer protein inhibitors failed to improve outcomes despite promising observational data and biological plausibility. In the Cardiac Arrhythmia Suppression Trial of class IC antiarrhythmics to suppress premature ventricular complexes, biomarker-targeted therapy increased mortality. Contemporary biomarkers, including lipoprotein(a), coronary artery calcium scoring, and high-sensitivity C-reactive protein, are increasingly used to refine risk and guide therapy. However, despite favorable guideline recommendations, randomized trials showing that biomarker-guided or biomarker-targeted treatment improves hard clinical endpoints are lacking. This review presents historical biomarker reversals in cardiology and critically appraises the evidence supporting emerging biomarkers. Our core argument is that practice recommendations for biomarker-guided therapy should await appropriately designed randomized trials adequately powered for cardiovascular events and mortality.

Cardiology in Review
Mayo Clinic (US), Alfaisal University (SA), Henry Ford Health System (US), University of Washington (US), University of Michigan (US), Henry Ford Hospital (US), Michigan Medicine (US)
Good health and well-being
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon